Exhibit 99.1 Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 BOTHELL, Wash., November 7, 2024 – Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, a ...

Clinical Development & Pipeline Programs - Athira Pharma is advancing ATH-1105, a next-generation, orally administered small molecule drug candidate, as a potential treatment for ALS and other neurodegenerative diseases [2][4] - ATH-1105 has shown preclinical efficacy in reducing plasma neurofilament light chain (NfL) levels, improving motor and nerve function, enhancing neuronal survival, and improving biomarkers of inflammation and neurodegeneration in ALS models [2] - The company is conducting a Phase 1 trial (NCT 06432647) in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of ATH-1105, with completion expected by year-end 2024 and plans to dose ALS patients in 2025 [5] - Fosgonimeton (ATH-1017), a drug candidate for Alzheimer's disease, did not meet primary or key secondary endpoints in the LIFT-AD Phase 2/3 trial, though biomarker and subgroup data were directionally consistent with its neuroprotective mechanism [6] Financial Results - Cash, cash equivalents, and investments totaled $68.9 million as of September 30, 2024, down from $147.4 million as of December 31, 2023 [8] - Net cash used in operations was $71.2 million for the nine months ended September 30, 2024, compared to $74.5 million for the same period in 2023 [8] - R&D expenses decreased to $17.9 million for Q3 2024 from $27.2 million in Q3 2023, while G&A expenses remained stable at $7.6 million compared to $7.8 million in the prior year [8] - The company accrued $4.1 million in legal expenses related to a U.S. Department of Justice investigative demand [8] - Net loss for Q3 2024 was $28.7 million ($0.75 per share), compared to a net loss of $33.0 million ($0.87 per share) in Q3 2023 [8] Strategic Initiatives - Following the topline results of the LIFT-AD trial, Athira is exploring strategic alternatives to maximize stockholder value, including potential partnerships, while pausing further development of fosgonimeton [7] - The company has engaged Cantor Fitzgerald & Co. as an advisor in the process of exploring strategic alternatives [7] Company Overview - Athira Pharma is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration by modulating the neurotrophic HGF system [9]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - ATHA Energy Corp. has entered into definitive option agreements with Terra Uranium Ltd. allowing T92 to acquire a 70% interest in ATHA's Spire and Horizon properties, while ATHA can earn up to a 60% interest in T92's Pasfield Lake property [1] Spire Horizon Option - T92 is required to incur a minimum of $4,750,000 in exploration expenditures to earn a 70% interest in the Spire Horizon Projects, with specific expenditure milestones set for December 2024, September 2025, September 2026, September 2027, and September 2028 [2] - Upon meeting the first three expenditure milestones, a joint venture will be formed with T92 and ATHA each holding a 50% participating interest, which will adjust to 70% for T92 and 30% for ATHA after the fourth and fifth expenditures [3] Pasfield Option - T92 grants ATHA four separate options to acquire interests in the Pasfield Project, each requiring specific exploration expenditures or successful drilling activities to earn a 15% interest [4][5] - After exercising all Pasfield Options, ATHA can convert its interests into a 1% net smelter returns royalty, with a maximum of 4% [6] - A joint venture will be formed on the Pasfield Project upon completion of the fourth option, with T92 holding an initial 40% interest and ATHA holding 60% [6] Investor Relations Agreements - ATHA has extended its agreement with Hybrid Financial Inc. for an additional three months, and has also extended its agreement with Gold Standard Media LLC for three months, subject to TSX Venture Exchange approval [7] - The marketing campaign with Creative Direct Marketing Group Inc. has been deferred due to market conditions, with no additional costs incurred beyond an initial fee [7] Company Overview - ATHA Energy Corp. is focused on the acquisition, exploration, and development of uranium assets, holding a portfolio that includes three 100%-owned post-discovery uranium projects and the largest cumulative prospective exploration land package exceeding 8.5 million acres in prominent uranium basins [9]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] Group 2 - The company specializes in various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [2] - Proactive adopts technology to enhance workflows and improve content production [3] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [3]

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025  Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal he ...

Shares of Athira Pharma, Inc. (ATHA) plunged 72.2% in after-hours trading on Sep 3 after the company announced disappointing top-line data from the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer’s disease (AD).The LIFT-AD study investigated once-daily fosgonimeton (40 mg) subcutaneous injection versus placebo over a treatment period of 26 weeks in mild-to-moderate AD patients.The study did not meet the primary endpoint which was th ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...